Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management.
Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80,000 employees in more than 150 countries worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan.
Roche was founded in 1896, headquartered in Basel, Switzerland. Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics.
Roche has had a presence in Singapore since 1973 and has since been striving to meet the needs of patients, healthcare professionals and researchers. In Singapore, we have three broad areas of operation: Pharmaceuticals, Diagnostics and Manufacturing.
In Singapore, Roche Pharmaceuticals is active in the following Disease Biology Areas:
Central nervous system
Many of our products ranked amongst the top selling products in the local pharmaceuticals market.
Singapore serves as the regional headquarters for Roche Diagnostics. Our regional headquarters is responsible for all aspects of sales and marketing within the Asia Pacific region (excluding Japan), for the implementation of global processes at the regional level and for company management in line with local regulations and practices.
We are committed to providing our customers with innovative, cost effective, timely and reliable diagnostic systems and solutions that will improve patient outcomes and potentially reduce healthcare costs for society.
Roche Technical Operations is a fully-owned Roche subsidiary and was established in Singapore in 2009. With a combined investment of approximately USD500 million, the site is comprised of two state-of-the-art facilities which use two different production technology platforms to manufacture biologic medicines. The facilities occupy approximately 12.6 hectares at the Tuas Biomedical Park.
The Singapore site is an important part of Roche’s global manufacturing network, which includes biotechnology facilities in California (USA), Penzberg (Germany) and Basel (Switzerland). Roche Singapore Technical Operations is expected to be the first company in Singapore to produce licensed biotherapeutics using recombinant DNA technologies.
Innovation is our answer to our medical challenges.
Every day our ideas and research help to save patients' lives.
Innovation is the backbone of Roche’s strategy, and it requires perseverance and a long-term perspective. That is why Roche spent almost 10 billion Swiss francs (20% of total sales) on R&D in 2009. We will continue to increase our R&D budget.
Roche Diagnostics has R&D facilities in Europe and the United states, augmented by a network of alliances and partnerships giving it broad access to key technologies.
Close cooperation between the Pharmaceuticals Division and Roche Diagnostics is a key strategic advantage for our company. The two divisions can share intellectual property, technologies and research findings freely. Among other things, this allows Roche to combine and leverage both divisions’ leadership in the key field of molecular biology.
In addition, it enables diagnostics expertise to be seamlessly integrated into all parts of the pharmaceuticals R&D process. This is central to Roche’s goal of advancing personalized healthcare, an approach that seeks to tailor treatments to specific patient subpopulations based on emerging scientific understanding of biology and disease at the molecular level.